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Objectives: To assess associations between uCTX-II or uCIIM and severity of hip pain in patients with
mild-moderate hip osteoarthritis (OA) over a 2-year period, and establish whether the level of these
biomarkers at baseline could estimate a speciﬁc trajectory of hip pain.
Design: A cohort study with a 2-year follow-up and 6-monthly measurements of urinary biomarkers
(uCTX-II and uCIIM) and symptom severity. Patients were recruited from general practices. The primary
outcome was hip pain, measured with the Western Ontario and McMasters University Osteoarthritis
Index (WOMAC) subscale and the Visual Analog Scale (VAS). Associations between hip pain and bio-
markers were assessed using linear mixed-model analysis for repeated measurements. Five previously
identiﬁed pain trajectories were used as outcome to investigate whether the level of biomarkers at
baseline could estimate membership in one of the trajectories using multinomial regression analysis.
Results: LoguCTX-II and loguCIIM were not associated with WOMAC pain or VAS pain during the 2-year
follow-up. Patients in the highly progressive pain trajectory and the moderate pain trajectory were more
likely to have a higher loguCTX-II at baseline (OR 6.7; 95% CI 1.6e28.2 and OR 4.8; 95% CI 1.0e22.8,
respectively) than patients in the mild pain trajectory.
Conclusion: This study shows that in patients with mild-moderate hip OA the urinary biochemical
markers uCTX-II and uCIIM are not cross-sectionally associated with hip pain during the 2-year follow-
up. Because the uCTX-II level estimated a progressive or moderate hip pain trajectory, this correlation
needs to be conﬁrmed in additional patients with hip OA.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is characterized by slowly progressive
damage of synovial joint tissues, including cartilage destruction
and alterations of the bone and synovial tissue. Signs andto: D.M.J. Dorleijn, Erasmus
eneral Practice, PO Box 2040,
4196.
.J. Dorleijn), p.luijsterburg@
ience.com (A.C. Bay-Jensen),
mk@nordicbioscience.com
endaal), p.k.bos@erasmusmc.
Bierma-Zeinstra).
ternational. Published by Elsevier Lsymptoms of OA include joint pain, stiffness and disability.
Although radiography is used to conﬁrm OA in clinical practice,
speciﬁc OA signs (such as joint space narrowing) are only visible
after signiﬁcant cartilage degradation has taken place1.
Biochemical markers, or biomarkers, are deﬁned as character-
istics that are objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention2. The availability of
biomarkers that can assist in diagnosing early-stage OA, predicting
OA progression, and assessing therapeutic responses could improve
early diagnosis and help monitor the effect of OA treatment. In OA,
biomarkers of interest originate from bone, synovial tissue, and the
articular cartilage3.td. All rights reserved.
D.M.J. Dorleijn et al. / Osteoarthritis and Cartilage 23 (2015) 57e6258The articular cartilage is composed of two primary matrix pro-
teins: type II collagen and aggrecan. During cartilage erosion, type II
collagen is sequentially degraded by enzymes, as matrix metal-
loproteinases (MMP). The resulting protein fragments, called neo-
epitopes, are released into the circulation and excreted in the urine;
these fragments could serve as biomarkers. Two of these bio-
markers of type II collagen metabolism are type II collagen C-
telopeptide (CTX-II) and MMP-derived CIIM. Urinary (u) CTX-II has
been investigated most extensively and associations have been
shown between uCTX-II and radiographic hip joint space narrow-
ing, and between uCTX-II and hip pain4,5. CIIM has recently been
identiﬁed as a collagen type II neoepitope; serum CIIM levels are
reported to be higher in individuals with knee OA than in those
without knee OA6. Although CIIM was originally identiﬁed in urine
by mass spectrometry, to date no study has clinically validated the
marker in urine as a marker of OA.
Most previous studies have investigated the relationship
between biomarkers and symptoms cross-sectionally5, or studied
the relation between biomarkers and prediction of structural
damage7. Moreover, because the performance of biochemical
markers has been investigated more frequently in knee OA than in
hip OA, our knowledge on the performance of biomarkers in hip OA
is limited5.
Studying symptomatic progression requires repeated measure-
ments and the ability to discriminate progressing disease fromnon-
progressing disease. Latent class growth analysis (LCGA) has this
ability and is a technique that ﬁnds clinically meaningful groups of
people who are similar in their responses to measured variables,
e.g., pain scores8. Recently, LCGA applied to a longitudinal dataset of
patients with hip OA discriminated between ﬁve different pain
trajectories over a 2-year period of follow-up, i.e., high pain,
moderate pain, mild pain, regularly progressive pain and highly
progressive pain8. If biomarkers could help in predicting which
group patients belong to, this could be of considerable clinical
value.
The objective of this study was to assess whether there is an
association between uCTX-II or uCIIM and perceived hip pain of
patients with mild-moderate hip OA, over a 2-year period with 6-
monthly measurements of urinary biomarkers and hip pain. The
secondary objective was to assess whether these biomarkers could
help to estimate a speciﬁc trajectory of hip pain over the 2-year
period.
Methods
Study population
The study population consisted of primary care patients diag-
nosed with hip OA (n ¼ 222) who participated in a prospective
randomized controlled trial that assessed the effect of glucosamine
sulfate (the GOAL trial; ISRCTN54513166)9e11. This trial recruited
prevalent cases of patients with hip complaints from databases of
general practices in the Netherlands. Patients were eligible if they
met one of the American College of Rheumatology (ACR) criteria for
hip OA12. Patients who had undergone or were awaiting total hip
replacement (THR) surgery and patients with a Kellgren and Law-
rence (KL) score of 4 were excluded13. Patients were also excluded if
they had renal disease, liver disease, diabetes mellitus, or were
already taking glucosamine. Also excluded were patients with a
disabling comorbid disease that would make visits to the research
center impossible, and those unable to complete questionnaires in
Dutch.
Eligible patients were randomly assigned to receive either
1500 mg of oral glucosamine sulfate once daily or placebo over a
period of 2 years. The Medical Ethics Committee of the ErasmusUniversity Medical Center approved the study design, and all
patients provided written informed consent. A detailed description
of the study design and outcomes has been published else-
where9e11. The GOAL trial showed that glucosamine sulfate was not
superior to placebo in reducing symptoms and progression of hip
OA. One of the secondary outcomes of this trial was biomarker level
of CTX-II and a promising new marker CIIM assessed in urine
samples10.
Biochemical markers
The biomarkers uCTX-II and uCIIM were measured in second
morning void urine at ﬁve time points: at baseline, and at 6, 12, 18
and 24-months follow-up. The samples were stored at 80C. The
samples were collected from September 2003 until March 2006.
The samples were analyzed in 2010. Prior to measurement the
urine samples were thawed, vortexed and spun down to ﬁrst mix
the samples and pellet potential debris. Prolonged storage test of
the assays for up to 12 years showed no effect of storage on the
levels of the biomarkers. U-CTX-II was measured by the
commercially available Cartilaps® ELISA (IDS Nordic, Herlev,
Denmark). Urinary CIIM was measured by an in-house constructed
EIA targeting the neo-epitope RDGAAGY derived from MMP
cleavage of type II collagen6,14. For both assays, intra- and inter-
assay variations were <8 and <12% for the urine measurement.
Samples were run in duplicates and repeated if CV% was >15%.
Both markers were normalized for the amount of creatinine (creat)
in the urine. If the level of creat was below the lower limit of
detection, then the level was set to the lowest detectable level
(1 umol/mL creat). In our trial we did not measure CTX-II and CIIM
in serum.
Clinical outcomes
The outcome was severity of hip pain reported by the patient.
This was measured 3-monthly during the 2-year follow-up with
two validated measuring instruments: the Western Ontario and
McMasters University Osteoarthritis Index (WOMAC) subscale for
hip pain and the Visual Analog Scale (VAS; range 0e100, 0 indicates
no pain, 100 indicates unbearable pain)15. The WOMAC subscale
was converted to a 0e100 score (0 indicates no symptoms, 100
indicates unbearable pain). The WOMAC is recommended by the
Osteoarthritis Research Society International for use in clinical
trials in patients with hip OA tomeasure pain severity. TheWOMAC
asks patients about their pain in the previous 2 days; the VAS pain
was scored as the average hip pain during the previous 7 days. If
patients had a THR during follow-up, available data were included
in the analysis until surgery; data collected after surgery were
assumed to be missing.
Pain trajectories
Recently, using the 3-monthly repeated pain measurements
during 2-year follow-up, ﬁve distinct trajectories of hip pain were
identiﬁed in the GOAL data8. The LCGA differentiated the following
trajectories: mild pain (n ¼ 69), moderate pain (n ¼ 31), high pain
(n¼ 31), regularly progressive pain (n¼ 48), and highly progressive
pain (n ¼ 42). A more detailed description of the determination of
these pain trajectories has already been published8. Three of these
ﬁve trajectories started with low baseline pain scores; however,
over time the trajectories show important differences. The ‘mild
pain’ trajectory stayed at the same low pain level during the 2-year
follow-up, the ‘moderate’ trajectory showed a moderate progres-
sion in pain score, and the ‘highly progressive’ trajectory showed a
rapid progression in pain score.
Table I
Patient characteristics at baseline
Characteristic Patients (n ¼ 222)
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whether the level of biomarkers at baseline could estimate mem-
bership in one of the trajectories.Gender (n, %) Female 154 (69.4)
Age in years (mean, SD) 63.4 (9.0)
BMI (kg/m2) (mean, SD) 28.0 (4.7)
Duration of complaints (n, %) <3 years 103 (46.4)
3 years 119 (53.6)
Knee OA (KL  2) (n, %) 68 (30.6)
Hand OA (KL  2) (n, %) 116 (52.3)
Radiologic hip OA (n, %) KL < 2 114 (51.4)
KL  2 108 (48.6)
uCIIM pg/umol creat (median, IQR) 61.7 (51.5)
uCTX-II pg/umol creat (median, IQR) 332 (355)
WOMAC pain (0e100) 34.2 (23.1)
WOMAC function (0e100) 35.1 (22.9)
WOMAC stiffness (0e100) 42.6 (25.2)
VAS hip pain (0e100) 32.4 (25.9)
KL¼ Kellgren& Lawrence grading of radiologic OA, uCIIM¼ type II collagen marker,
uCTX-II ¼ C-terminal telopeptides of type II collagen, creat ¼ creatinine,
WOMAC ¼ Western Ontario and McMaster Universities (0 indicates no pain),
VAS ¼ Visual Analog Scale (0 indicates no pain), SD ¼ standard deviation,
IQR ¼ interquartile range.
Table IIStatistical analysis
Data were analyzed using multivariable linear mixed models for
repeated measurement to assess the cross-sectional associations
between patients' perceived hip pain and uCTX-II and/or uCIIM
over the 2-year period. The linear mixed model adjusts for the
within-patient correlation for the outcomes at different measure-
ments in each patient and uses each outcome from each patient as a
separate observation.
To obtain a normal distribution of uCTXII pg/umol creat and
uCIIM pg/umol creat, the natural logarithm of both was taken. The
unstructured covariance structure was used, since this yielded the
lowest Akaike's Information Criterium (AIC).
Covariates used in the model were: age, gender and body mass
index (BMI). To minimise the bias in our estimation of the associ-
ation between biomarker and pain we performed the 6-step
approach by Pearl16. This yielded the following covariables: allo-
cated treatment, duration of hip complaints (dichotomised to <3
years vs 3 years), presence of hand OA or knee OA and severity of
radiologic hip OA.
Knee OA and hand OA at baseline were deﬁned as KL score 2
as seen on the X-ray. Radiologic hip OA was deﬁned as OA of the
index hip (KL  2) vs no radiologic hip OA (KL < 2). All covariates
were included in the model as ﬁxed factors.
A subgroup analysis was performed with patients with minimal
radiologic hip OA (KL < 2) and patients with deﬁnite radiologic hip
OA (KL  2).
Multinomial regression analysis was used to assess if the base-
line level of biomarkers estimates the probability of membership in
one of the ﬁve trajectories of hip pain. Due to the division into ﬁve
pain trajectories, the study population per trajectory was relatively
small (n ¼ 31 to n ¼ 69). Therefore, in the multinomial analysis we
did not adjust for other baseline variables. However, we studied
other baseline variables also using univariate multinomial regres-
sion analysis. Since wewere interested in the additional value of an
imaging marker (radiography), we performed an explorative anal-
ysis for uCTX-II and uCIIM adjusted for baseline radiographic hip
OA. All analyses were conducted using SPSS version 20.0.Results of multivariate linear mixed-model analysis of biochemical markers and
symptom severity during 2 years of follow-up with 6-monthly measurements
Variable WOMAC pain (0e100)
(n ¼ 213)
VAS pain (0e100)
(n ¼ 213)
Coefﬁcient
(95% CI)
P-value Coefﬁcient
(95% CI)
P-value
Gender (female) 8.1 (2.4e13.8) <0.01 7.5 (1.2 to 13.8) 0.02
Age (years) 0.0 (0.3 to 0.3) 0.90 0.1 (0.3 to 0.4) 0.68
BMI (kg/m2) 1.0 (0.4e1.5) <0.01 1.1 (0.5e1.7) <0.01
Duration of
complaints
(>3 years)
7.2 (2.1e12.4) <0.01 7.0 (1.4e12.6) 0.02
Concomitant knee OA 1.4 (4.5 to 7.3) 0.64 2.9 (9.3 to 3.5) 0.37
Concomitant hand OA 3.4 (9.1 to 2.3) 0.24 2.7 (8.9 to 3.5) 0.39Results
Study population
The baseline characteristics of the 222 patients participating in
the GOAL trial are presented in Table I. The mean age was 63.4 (SD
9.0) years and 69.4% of patients were female. The mean WOMAC
pain scorewas 34.2 (SD 23.1) and themean VAS pain scorewas 32.4
(SD 25.9). The duration of hip complaints was 3 years in 119
(53.6%) patients; 108 (48.6%) patients had a minimumKL score of 2.
Of all patients, 20 received a THR during follow-up.Radiologic hip OA
(KL  2)
3.2 (2.2 to 8.6) 0.24 6.6 (0.7 to 12.5) 0.03
Treatment (placebo) 2.9 (7.9 to 2.1) 0.25 2.0 (7.4 to 3.5) 0.48
LoguCTX-II
(pg/umol creat)
2.6 (1.9 to 7.1) 0.26 4.3 (1.2 to 9.9) 0.13
LoguCIIM
(pg/umol creat)
1.6 (5.7 to 2.5) 0.44 0.7 (5.8 to 4.3) 0.77
uCTX-II ¼ C-terminal telopeptides of type II collagen, uCIIM ¼ type II collagen
marker, creat ¼ creatinine, CI ¼ conﬁdence interval, bold ﬁgures indicate P < 0.05.
The coefﬁcient indicates the magnitude of change in pain score expected from a 1-
unit change in the variable.Biochemical markers
The median uCIIM pg/umol creat was 61.7 (IQR 51.5) and the
median uCTX-II pg/umol creat was 332 (IQR 355). At baseline,
biomarkers for 197 (89%) patients were available for analysis,
compared with 177 (80%) patients at 6-months follow-up, 190
(86%) at 12 months, 186 (84%) at 18 months and 187 (84%) patients
at 24-months follow-up.Associations between clinical outcomes and biochemical markers
The results of the multivariable adjusted mixed-model analysis
are presented in Table II. Neither loguCTX-II nor loguCIIM were
cross-sectionally associated with WOMAC pain or VAS pain during
the 2-year follow-up. Covariates associated with WOMAC pain
were: BMI (coefﬁcient 1.0; 95% CI 0.4e1.5), female gender (coefﬁ-
cient 8.1; 95% CI 2.4e13.8) and duration of complaints (coefﬁcient
7.2; 95% CI 2.1e12.4). Covariates associated with VAS pain were:
BMI (coefﬁcient 1.1; 95% CI 0.5e1.7), female gender (coefﬁcient 7.5;
95% CI 1.2e13.8), duration of complaints (coefﬁcient 7.0; 95% CI
1.4e12.6) and radiologic hip OA (KL  2) (coefﬁcient 6.6; 95% CI
0.7e12.5).
The subgroup analysis of patients with deﬁnite radiographic OA
(K&L  2) at baseline (n ¼ 108) showed a signiﬁcant association
between loguCTX-II and VAS pain (coefﬁcient 17.1; 95% CI
7.7e26.5). The association between loguCTX-II and WOMAC pain
was not signiﬁcant in the deﬁnite radiographic OA group, nor were
the associations between loguCIIM and WOMAC pain or VAS pain.
Table IIa
Results of multivariate linear mixed-model analysis of biochemical markers and
symptom severity during 2 years of follow-up with 6-monthly measurements;
subgroup of patients with minimal radiologic hip OA (KL < 2)
Variable WOMAC pain (0e100)
(n ¼ 213)
VAS pain (0e100) (n ¼ 213)
Coefﬁcient (95% CI) P-value Coefﬁcient (95% CI) P-value
Gender (female) 11.5 (2.2 to 20.8) 0.02 12.6 (2.4 to 22.8) 0.02
Age (years) 0.2 (0.3 to 0.7) 0.35 0.3 (0.2 to 0.9) 0.21
BMI (kg/m2) 1.2 (0.4 to 1.9) <0.01 1.2 (0.3 to 2.0) <0.01
Duration of
complaints
(>3 year)
3.2 (4.1 to 10.5) 0.39 5.7 (2.4 to 13.7) 0.17
Concomitant
knee OA
1.7 (7.1 to 10.5) 0.71 1.7 (11.3 to 8.0) 0.73
Concomitant
hand OA
4.2 (12.2 to 3.8) 0.30 6.2 (25.0 to 2.5) 0.16
Treatment
(placebo)
0.7 (8.0 to 6.7) 0.85 0.4 (7.6 to 8.5) 0.91
LoguCTX-II
(pg/umol creat)
1.3 (4.0 to 6.4) 0.63 3.4 (9.9 to 3.0) 0.30
LoguCIIM
(pg/umol creat)
2.0 (7.4 to 3.4) 0.46 4.8 (1.6 to 11.3) 0.14
uCTX-II ¼ C-terminal telopeptides of type II collagen, uCIIM ¼ type II collagen
marker, creat ¼ creatinine, CI ¼ conﬁdence interval, bold ﬁgures indicate P < 0.05.
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associations were found between loguCTX-II, loguCIIM and the pain
scores (see web-based Table IIa and b).
Multinomial regression analysis showed that, compared to pa-
tients in the mild pain trajectory, patients in the highly progressive
pain trajectory were more likely to have a higher loguCTX-II (OR
6.7; 95% CI 1.6e28.2) at baseline (Table III). The odds ratio (OR) for
loguCTX-II was higher than that for the duration of complaints or
severity of radiologic OA. Patients in the moderate pain trajectory
were also more likely to have a higher loguCTX-II at baseline (OR
4.8; 95% CI 1.0e22.8) compared to the mild pain trajectory.
After adjustment for the imaging marker (radiologic OA), pa-
tients in the highly progressive pain trajectory were more likely to
have a higher loguCTX-II (OR 4.6; 95% CI 1.0e19.9; P 0.04) at
baseline.
LoguCTX-II explained 5% of the variance of the model and
loguCIIM explained 1% of the variance (Table III).Table IIb
Results of multivariate linear mixed-model analysis of biochemical markers and
symptom severity during 2 years of follow-up with 6-monthly measurements;
subgroup of patients with deﬁnite radiologic hip OA (KL  2)
Variable WOMAC pain (0e100)
(n ¼ 213)
VAS pain (0e100) (n ¼ 213)
Coefﬁcient
(95% CI)
P-value Coefﬁcient
(95% CI)
P-value
Gender (female) 5.8 (1.7 to 13.3) 0.13 3.0 (5.0 to 11.1) 0.46
Age (years) 0.1 (0.5 to 0.3) 0.67 0.1 (0.6 to 0.3) 0.54
BMI (kg/m2) 0.6 (0.3 to 1.4) 0.20 1.0 (0.1 to 1.9) 0.03
Duration of
complaints
(>3 year)
10.7 (3.3 to 18.0) <0.01 9.7 (1.8 to 17.6) 0.02
Concomitant
knee OA
1.9 (6.0 to 9.9) 0.63 1.7 (10.1 to 6.7) 0.70
Concomitant
hand OA
2.2 (10.5 to 6.2) 0.61 2.2 (6.8 to 11.1) 0.63
Treatment (placebo) 6.7 (13.8 to 0.4) 0.06 5.8 (13.4 to 1.8) 0.13
LoguCTX-II
(pg/umol creat)
6.0 (1.8 to 13.8) 0.13 17.1 (7.7 to 26.5) <0.01
LoguCIIM
(pg/umol creat)
0.4 (6.7 to 5.8) 0.90 6.3 (14.1 to 1.5) 0.12
uCTX-II ¼ C-terminal telopeptides of type II collagen, uCIIM ¼ type II collagen
marker, creat ¼ creatinine, CI ¼ conﬁdence interval, bold ﬁgures indicate P < 0.05.Discussion
In patients with mild-moderate hip OA, urinary CTX-II and CIIM
were not cross-sectionally associated with patients' perceived
severity of hip pain (measured with WOMAC pain and VAS pain)
over the 2-year follow-up. Patients in the moderate pain trajectory
and in the highly progressive pain trajectory were more likely to
have a higher loguCTX-II at baseline than patients in the mild pain
trajectory.
Results of earlier studies on the relationship between uCTX-II
and patients' perceived pain are conﬂicting. One cross-sectional
study in patients with knee OA showed no association between
uCTX-II and WOMAC total score, and uCTX-II and WOMAC pain
score17. However, another study in patients with knee OA suggested
that patients with a high level of uCTX-II at baseline have a sig-
niﬁcant correlation with WOMAC scores, with a peak at 18-months
follow-up18. In hip OA the correlation between uCTX-II and pain has
also been shown to be cross-sectional4.
Urinary CIIM has not been investigated as extensively as uCTX-II.
Although serum CIIM levels are reported to be higher in patients
with radiographic knee OA than in thosewithout radiographic knee
OA, its relationshipwith pain has not previously been investigated6.
Serum CIIM levels are reported to be somewhat predictive for
structural progression in ankylosing spondylitis19 and for treat-
ment response in rheumatoid arthritis20.
Although both CTX-II and CIIM are neoepitopes of type II
collagen, clear histological differences have been observed which
may explain differences in results between the two markers. CTX-II
seems to be released from the eroded and ﬁbrillated surface of the
OA cartilage as well as the interface between the subchondral bone
and the calciﬁed cartilage21. In contrast, CIIM seems to be released
from the articular cartilage6. In other words, CTX-II may be asso-
ciated to a greater extent with the innervated bone tissue, whereas
CIIM may be uniquely derived from the non-innervated articular
cartilage. In our data uCIIM and uCTX-II were not correlated to each
other.
The relationship between uCTX-II and radiographic OA has been
reported previously in both knee and hip OA in cross-sectional
designs4,7,22. Moreover, Reijman et al. showed that in patients
with hip pain, the association between uCTX-II levels and radio-
graphic OAwas stronger (OR 20.4) than in patients without hip pain
(OR 3.0)7.
A strength of our study is the longitudinal design with ﬁve
repeated follow-up measurements of urinary biomarkers and pain
scores during 2-year follow-up; this allowed to explore the rela-
tionship between biomarkers and pain over time. Although cross-
sectional associations between biomarkers and clinical outcomes
have previously been reported, longitudinal associations have not
yet been extensively investigated. For clinical use, it would be
interesting to have biomarkers that are associated with future
clinical outcomes of OA over a longer follow-up period. Then these
biomarkers could be used to monitor disease progression or
treatment effects over time. Another strength is that in our linear
mixed models we were able to correct for some well-known
covariables such as age, BMI and severity of radiologic hip OA.
The study also has some limitations. The ﬁrst is that althoughwe
have information on knee OA and hand OA, we do not know
whether knee OA or hand OA was unilateral of bilateral.
UCTX-II and uCIIM are not speciﬁc markers for the hip, but are
released in every joint. Therefore, it would be interesting to see
whether the results are different when a weighted adjustment
could be done, counting the number of joints affected by OA. In
addition, it would also be interesting to adjust for lower back OA,
since an association has been shown between CTXII and disc space
narrowing23.
Table III
Multinomial binary regression analysis for individual baseline variables for the four trajectories of hip pain (mild hip pain trajectory was used as reference group)
Moderate pain Always pain Regularly
progressive pain
traject
Highly progressive
pain traject
Explained variance
by model
n ¼ 31 n ¼ 32 n ¼ 48 n ¼ 42
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Gender (female) 2.1 0.8e5.5 2.2 0.8e5.7 1.2 0.6e2.6 1.5 0.7e3.5 2%
Duration of hip complaints (3 years) 1.8 0.8e4.2 3.2 1.3e7.8 1.6 0.8e3.3 2.6 1.2e5.8 5%
Concomitant knee OA 2.3 0.9e6.0 2.5 1.0e6.5 3.4 1.5e7.9 2.6 1.1e6.4 5%
Concomitant hand OA 0.8 0.4e2.0 1.5 0.6e3.5 1.8 0.8e3.7 1.5 0.7e3.3 2%
Radiologic hip OA (KL  2) 1.9 0.8e4.4 3.3 1.4e8.0 2.0 0.9e4.3 3.3 1.5e7.2 6%
Age 1.0 0.9e1.0 1.0 1.0e1.1 1.0 1.0e1.1 1.0 1.0e1.1 2%
BMI* 1.1 1.0e1.3 1.2 1.1e1.4 1.1 1.0e1.2 1.2 1.1e1.3 9%
LoguCTX-II pg/umol creat** 4.8 1.0e22.8 4.1 0.9e19.5 1.5 0.5e5.1 6.7 1.6e28.2 5%
LoguCIIM pg/umol creat** 2.3 0.5e11.9 1.5 0.3e7.4 0.9 0.2e3.4 1.7 0.4e7.2 1%
uCTX-II ¼ C-terminal telopeptides of type II collagen, uCIIM ¼ type II collagen marker, creat ¼ creatinine, y ¼ years, *n ¼ 220, **n ¼ 197, bold ﬁgures indicate P < 0.05.
D.M.J. Dorleijn et al. / Osteoarthritis and Cartilage 23 (2015) 57e62 61Another possible limitation is the use of glucosamine in half of
the patients. Although the results of the GOAL trial showed that
clinical symptoms and radiographic progression of hip OA did not
differ between active treatment and placebo at any follow-up
measurement9, other studies reported that glucosamine adminis-
tration signiﬁcantly decreased uCTX-II levels24. Therefore, a
possible effect of glucosamine on uCTX-II levels cannot be ruled
out. However, because analyses with and without adjustment for
treatment yielded the same results, we believe that the contribu-
tion of a possible effect of glucosamine to the model is small.
In addition, we had no information on the menopausal status of
the included women. This might have inﬂuenced the results, as it is
reported that postmenopausal women show higher levels of uCTX-
II than premenopausal women25. However, we believe that this
would have little inﬂuence in the present study because the mean
age of our populationwas 63 years (an agewhenmost women have
reached menopausal status). To further study the possible effect of
the menopausal status, we analyzed men and women separately. In
both groups no association was found between uCTX-II or uCIIM
and severity of hip pain.
The GOAL study recruited prevalent cases of patients registered
with hip OA or patients with symptoms associated with hip OA in
the medical records of the general practices. These patients were
contacted by their general practitioner (GP) and informed about the
study. However, because a selection of patients might have
responded to the GP's invitation, there is a possibility of selection
bias. Also, our results cannot be generalized to patients referred to
secondary care for complaints of hip OA.
Finally, the results for the prediction of the course of pain were
only analyzed bivariately because the numbers of patients in the
ﬁve pain trajectories were too small to perform multivariate anal-
ysis. A larger patient population would allow exploring the asso-
ciation between uCTX-II and progressive pain related to other
variables such as BMI and duration of complaints to see whether
some of the covariates could bee confounders. It would also show
whether uCTX-II has an additional value to predictors that are
easily assessed during history taking and physical examination.
Implications for clinical practice and research
During the 2-year follow-up, no cross-sectional association was
found between uCTX-II or uCIIM and severity of hip pain in patients
with clinical hip OA according to the ACR criteria registered in the
medical records of general practices. Baseline uCTX-II was related to
progressive pain trajectories during follow-up. Therefore, uCTX-II
might help to identify patients at risk for a progressive paintrajectory. However, this needs further investigation and, although
uCTX-II is commercially available, its value for the prognosis of an
individual patient remains unclear. Further studies should also
examine whether uCTX-II is a better predictor than other variables
that are easier to assess by the GP (e.g., duration of complaints,
gender), or variables alreadywidely used in clinical practice (e.g., X-
ray).
Based on this current work, we cannot recommend CIIM as a
biomarker in hip OA in clinical practice.
Conclusion
This study shows that, over a 2-year period, the urinary
biochemical markers uCTX-II and uCIIM were not cross-sectionally
associated with perceived hip pain of patients with hip OA. How-
ever, uCTX-II might be helpful to estimate a progressive pain tra-
jectory or a moderate pain trajectory over a 2-year period. This
needs further evaluation in studies with a larger sample size.
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